Idorsia Ltd
Hegenheimermattweg 91
Allschwil 4123
Switzerland
41 58 844 10 10
https://www.idorsia.com
版塊: Healthcare
行業: Biotechnology
全職員工:
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Jean-Paul Clozel M.D. | CEO & Exec. Director | 1.38M | 無 | 1955 |
| Mr. André C. Muller | Exec. VP & CFO | 無 | 無 | 1963 |
| Dr. Martine Clozel | Exec. VP & Chief Scientific Officer | 無 | 無 | 1955 |
| Mr. Andrew C. Weiss | Sr. VP and Head of Investor Relations & Corp. Communications | 無 | 無 | 1968 |
| Mr. Julien Gander L.L.M. | Sr. VP, Group Gen. Counsel & Company Sec. | 無 | 無 | 1979 |
| Mr. Alexander Khatuntsev | Sr. VP & Head of Global HR | 無 | 無 | 1978 |
| Dr. Guy Braunstein M.D. | Exec. VP & Chief Medical Officer | 無 | 無 | 1956 |
| Mr. Olivier Lambert | Sr. VP and Head of Global Pharmaceutical Devel. & Quality Assurance | 無 | 無 | 1966 |
| Mr. Markus A. Riederer | Sr. VP & Head of Drug Discovery Biology | 無 | 無 | 1962 |
| Mr. Christoph Boss | Sr. VP & Head of Drug Discovery Chemistry | 無 | 無 | 1968 |
描述
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
公司管治
截至 2023年10月1日 止，Idorsia Ltd 的 ISS 管治質素評分為 2。 Pillar 分數正在審核中：10；董事會：2；股東權利：1；現金賠償：6。
